论文部分内容阅读
目的探讨采用肺表面活性物质治疗新生儿呼吸窘迫综合征的临床效果。方法选择商丘市妇幼保健院2011年1月至2012年8月收治的新生儿呼吸窘迫综合征患儿43例。随机分为对照组20例与研究组23例。对照组患儿采取常规方法进行治疗,研究组患儿在对照组基础上联合运用肺表面活性物质治疗。评价两组患儿治疗前后症状、肺功能指标改善情况以及临床疗效与发生率。结果两组患儿治疗后症状及肺功能指标均较治疗前明显改善(P<0.05),研究组改善优于对照组(P<0.01)。临床疗效、患儿呼吸窘迫及严重并发症发生情况,研究组也均优于对照组(P<0.05)。结论肺表面活性物质治疗新生儿呼吸窘迫综合征安全且疗效显著,对提高新生儿呼吸窘迫综合征患儿肺功能及生命质量具有重要的意义。
Objective To investigate the clinical effect of pulmonary surfactant in the treatment of neonatal respiratory distress syndrome. Methods 43 cases of neonatal respiratory distress syndrome in Shangqiu MCH hospital from January 2011 to August 2012 were selected. Randomly divided into control group of 20 cases and study group of 23 cases. The control group of children treated by conventional methods, the study group children in the control group based on the combination of pulmonary surfactant treatment. Evaluation of two groups of children before and after treatment of symptoms and lung function indicators to improve the situation and clinical efficacy and incidence. Results After treatment, the symptoms and pulmonary function indexes of both groups were significantly improved (P <0.05), and the improvement of the study group was better than that of the control group (P <0.01). Clinical efficacy, respiratory distress in children and serious complications, the study group were also better than the control group (P <0.05). Conclusion Pulmonary surfactant treatment of neonatal respiratory distress syndrome is safe and effective, which is of great significance to improve pulmonary function and quality of life in neonates with respiratory distress syndrome.